Exact Sciences Corporation EXAS

NASDAQ Health technology USD

Exact Sciences Corporation (EXAS) is a molecular diagnostics company focused on the early detection and prevention of cancer. The company develops and commercializes non-invasive screening tests that help identify cancer at its earliest, most treatable stages. Its primary business involves cancer screening through advanced diagnostic technologies, with a particular emphasis on colorectal cancer detection. The company serves healthcare providers, patients, and healthcare systems by offering innovative diagnostic solutions that improve patient outcomes through early cancer detection. Its business model revolves around research and development of proprietary testing technologies, manufacturing diagnostic kits, and marketing these tests through direct sales forces and partnerships with healthcare institutions. The company operates clinical laboratories where it processes test samples and provides results to healthcare providers. Exact Sciences generates revenue primarily from the sale of its cancer screening tests, with its Cologuard test for colorectal cancer being a flagship product. The company also engages in precision oncology through additional diagnostic offerings that help guide cancer treatment decisions. Its operations include significant investments in research and development to expand its test portfolio and improve existing technologies.